Bladder defense mechanism
- PMID: 801214
Bladder defense mechanism
Abstract
In order for micro-organisms to infect the urinary tract they must adhere to the vesical mucosa so that they remain after voiding. Experiments in our laboratory demonstrated that the bladder has a self-protective mechanism capable of preventing bacterial adherence to the surface. Histochemical staining demonstrated that this substance is a mucopolysaccharide. Treatment of the mucosa with acid disrupted the protective layer and resulted in a 20 to 100-fold increase in bacterial adherence. Within 24 hours this layer reappeared and binding was again reduced to normal. This phenomenon was not related to microbial species or metabolic activity.
Similar articles
-
The primary antibacterial defense mechanism of the bladder.Invest Urol. 1975 Jul;13(1):72-8. Invest Urol. 1975. PMID: 1095522
-
Bladder surface mucin. Its antibacterial effect against various bacterial species.Am J Pathol. 1978 Nov;93(2):423-32. Am J Pathol. 1978. PMID: 362941 Free PMC article.
-
Bladder surface mucin. Examination of possible mechanisms for its antibacterial effect.Invest Urol. 1978 Nov;16(3):196-200. Invest Urol. 1978. PMID: 30735
-
Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms.Urol Clin North Am. 1986 Nov;13(4):563-8. Urol Clin North Am. 1986. PMID: 2877517 Review.
-
From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa.Mucosal Immunol. 2013 Nov;6(6):1041-53. doi: 10.1038/mi.2013.72. Epub 2013 Sep 25. Mucosal Immunol. 2013. PMID: 24064671 Review.
Cited by
-
Protease-activated receptor-2-mediated contraction in the rat urinary bladder: the role of urinary bladder mucosa.Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):211-3. doi: 10.1007/s00210-002-0687-y. Epub 2003 Jan 24. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12595964
-
Possible involvement of Ca2+-independent phospholipase A2 in protease-activated receptor-2-mediated contraction of rat urinary bladder.Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):588-91. doi: 10.1007/s00210-003-0753-0. Epub 2003 May 15. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12750876